US Neurology Editorial Board member, Stephen Silberstein (Thomas Jefferson University, Philadelphia, USA), discusses the most significant advances in the prevention and treatment of migraine in the last year.
- What do you consider the most important developments in migraine prevention and treatment in the last year? (0:04)
- What is the rationale for the use of anti epileptic drugs (AEDs) in the prevention and treatment of migraine? (0:49)
- Which AEDs do you recommend in the prevention of migraine and which might play a role in the future? (1:39)
- What is your opinion on the use of cannabinoids in the treatment of migraine? (2:13)
- What are the most exciting therapies currently in development in the field of migraine prevention and treatment? (3:19)
- Please summarize your highlights so far at this AAN meeting. (3:35)
Scientific Advisory Boards: Abide Therapeutics; Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Biohaven Pharmaceuticals; Cefaly; Curelator, Inc.; Dr. Reddy’s Laboratories; Egalet Corporation; GlaxoSmithKline Consumer Health Holdings, LLC; eNeura Inc.; electroCore Medical, LLC; Lilly USA, LLC; Medscape, LLC; NINDS; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.
Editorial Boards: Cephalalgia; Current Pain and Headache Reports; CNS Drugs; Topics in Pain Management; and Neurology.
Consultancies: Allergan; Amgen; eNeura; ElectroCore Medical; Mitsubishi Tanabe; Medtronic; Neuralieve; Pfizer; Supernus; and Teva.
Speakers’ Bureaus: Amgen; Teva; and Supernus.
Research Support, Commercial Entities (Past 2 years): GlaxoSmithKline; Allergan; Merck; Novartis; NIH; Neurolieve; MAP; Endo Now: Amgen; ElectroCore; Avanir; Allergan; Teva; and Lilly.
Research Support, Government Entities: NIH.
Research Support, Foundations and Societies: AHS and IHS.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Headache Disorders
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!